Advanced Solid Tumor trials recruiting in New York

All Advanced Solid Tumor trials nationally

Cities in New York

Recruiting trials in New York

• A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
  NCT07070232 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
  NCT05873686 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
  NCT06997029 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: Buffalo, New Hyde Park, New York
• A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
  NCT05932862 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
  NCT05902988 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
  NCT06657144 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: Lake Success, New York
• A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
  NCT06778863 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
  NCT06172478 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Buffalo, New York
• A Study of IDP-001 in Advanced or Metastatic Solid Tumors
  NCT07602842 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Buffalo, Lake Success
• A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
  NCT06561685 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
  NCT06465069 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Study of MGC026 in Participants With Advanced Solid Tumors
  NCT06242470 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: Lake Success
• A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
  NCT04104776 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Buffalo, New York, Rochester, The Bronx
• A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
  NCT05824975 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
  NCT07284186 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
  NCT04977453 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors
  NCT07166601 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
  NCT05245500 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: Mineola, New York, Port Jefferson Station
• Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)
  NCT05898399 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• Study of AVZO-021 in Patients With Advanced Solid Tumors
  NCT05867251 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Mineola, New York
• Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
  NCT04890613 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
  NCT06545942 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
  NCT05098132 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: Lake Success, New York
• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
  NCT04585750 · Phase: Phase 1, Phase 2 · Ages: 12 Years and older · Sex: All (male and female) · New York: New York